Literature DB >> 28099179

Traditional Sternotomy Versus Minimally Invasive Aortic Valve Replacement in Patients Stratified by Ejection Fraction.

Tom C Nguyen1, Vinod H Thourani, Justin Q Pham, Yelin Zhao, Matthew D Terwelp, Prakash Balan, Daniel Ocazionez, Catalin Loghin, Richard W Smalling, Anthony L Estrera, Joseph Lamelas.   

Abstract

OBJECTIVE: Low ejection fraction (EF < 40%) portends adverse outcomes in patients undergoing valvular heart surgery. The role of traditional median sternotomy aortic valve replacement (SAVR) compared with minimally invasive aortic valve replacement (MIAVR) in this cohort remains incompletely understood.
METHODS: A multi-institutional retrospective review of 1503 patients who underwent SAVR (n = 815) and MIAVR via right anterior thoracotomy (n = 688) from 2011 to 2014 was performed. Patients were stratified into two groups: EF of less than 40% and EF of 40% or more. In each EF group, SAVR and MIAVR patients were propensity matched by age, sex, body mass index, race, diabetes, hypertension, dyslipidemia, dialysis, cerebrovascular disease, cardiovascular disease, cerebrovascular accident, peripheral vascular disease, last creatinine level, EF, previous MI and cardiogenic shock, and the Society for Thoracic Surgeons (STS) score.
RESULTS: Among patients with an EF of 40% or more (377 pairs), patients who underwent MIAVR compared with SAVR had decreased intensive care unit hours (56.8% vs 84.6%, P < 0.001), postoperative length of stay (7.1 vs 7.9 days, P = 0.04), incidence of atrial fibrillation (18.8% vs 38.7%, P < 0.001), bleeding (0.8% vs 3.2%, P = 0.04), and a trend toward decreased 30-day mortality (0.3% vs 1.3%, P = 0.22). The STS scores were largely equivalent in patients undergoing MIAVR compared with SAVR (2.4% vs 2.6%, P = 0.09). In patients with an EF of less than 40% (35 pairs), there was no difference in intensive care unit hours (69% vs 72.6%, P = 0.80), postoperative length of stay (10.3 vs 7.2 days, P = 0.13), 30-day mortality (3.8% vs 0.8%, P = 0.50), or the STS score (3.3% vs 3.2%, P = 0.68).
CONCLUSIONS: Minimally invasive aortic valve replacement in patients with preserved EF was associated with improved short-term outcomes compared with SAVR. In patients with left ventricular dysfunction, short-term outcomes between MIAVR and SAVR are largely equivalent.

Entities:  

Mesh:

Year:  2017        PMID: 28099179     DOI: 10.1097/IMI.0000000000000338

Source DB:  PubMed          Journal:  Innovations (Phila)        ISSN: 1556-9845


  5 in total

1.  Aortic valve replacement in patients with a left ventricular ejection fraction ≤35% performed via a minimally invasive right thoracotomy.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; Angelo La Pietra; Maurice Mawad; Vicente Behrens; Esteban Escolar; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Aortic valve replacement using stented or sutureless/rapid deployment prosthesis via either full-sternotomy or a minimally invasive approach: a network meta-analysis.

Authors:  Kei Woldendorp; Mathew P Doyle; Paul G Bannon; Martin Misfeld; Tristan D Yan; Giuseppe Santarpino; Paolo Berretta; Marco Di Eusanio; Bart Meuris; Alfredo Giuseppe Cerillo; Pierluigi Stefàno; Niccolò Marchionni; Jacqueline K Olive; Tom C Nguyen; Marco Solinas; Giacomo Bianchi
Journal:  Ann Cardiothorac Surg       Date:  2020-09

3.  Improved operative and recovery times with mini-thoracotomy aortic valve replacement.

Authors:  Anna Olds; Siavash Saadat; Anthony Azzolini; Viktor Dombrovskiy; Karen Odroniec; Anthony Lemaire; Aziz Ghaly; Leonard Y Lee
Journal:  J Cardiothorac Surg       Date:  2019-05-09       Impact factor: 1.637

Review 4.  Bioprosthetic Aortic Valve Replacement in <50 Years Old Patients - Where is the Evidence?

Authors:  Amer Harky; Michael Man Yuen Suen; Chris Ho Ming Wong; Abdul Rahman Maaliki; Mohamad Bashir
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01

Review 5.  Minimally invasive aortic valve surgery.

Authors:  Lorenzo Di Bacco; Antonio Miceli; Mattia Glauber
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.